A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson’s disease potential biomarkers

Table 1 Groups’ demographic characterization and overview of the clinical data of the Parkinson’s disease group used for the discovery study

	Age at blood coll. (y)^a	Gender^b	Disease Duration (y)	Age at Onset (y)	Family history^c	HY scale^d	Total L-Dopa (converted CR + IR) (mg/day)^e
Parkinson's Disease Group	74 ± 7 [63, 83]	M:17 (54.8%); F: 14 (45.2%)	6.2 ± 3.8 [0.7, 15]	67.7 ± 7.4 [48, 80]	N: 30; Y:1	1.8 ± 1 [1, 4]	374.7 ± 288.7 [0, 1150]
Control Group	67 ± 10 [55, 83]	M: 16 (57.1%) F: 12 (42.9%)	–	–	–	–	–

^aAge at blood coll. (y): age at blood collection in years
^bThe individuals were divided into males (M) and females (F)
^cNumber of individuals with familiar history of PD (Y) and those without any familiar link to the disease (N)
^dHoehn and Yahr scale
^eTotal L-Dopa (converted CR + IR) (mg/day): calculated as the controlled release (CR) plus immediate-release (IR) in milligrams per day

ISSN: 2047-9158